Tirzepatide and 116-pound weight loss: what the data says

What's this video probably claiming?

Based on the caption, @alymfox is documenting a 116-pound weight loss over two years using tirzepatide, broken down by each dose escalation. This kind of breakdown, tracking how much weight dropped at 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, is popular in the GLP-1 TikTok community and functions as a personal progress chart. The implicit claim is that tirzepatide caused this weight loss at each successive dose, and that the trajectory is repeatable or representative. Viewers are also likely seeing this as evidence that tirzepatide outperforms other weight-loss options. That framing is partially supportable by clinical data, but personal results are not clinical predictions, and the dose-by-dose storytelling format tends to flatten a lot of medically relevant nuance, including starting BMI, comorbidities, diet changes, and adherence patterns.

What does the science actually show?

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) is the landmark study here. At 72 weeks, participants on 15mg tirzepatide lost a mean of 22.5% of body weight compared to 2.4% on placebo. That is genuinely significant, and it is more than what semaglutide 2.4mg achieved in the STEP-1 trial (Wilding et al., 2021, NEJM), where mean weight loss was around 14.9%. A 116-pound loss over two years is on the higher end of outcomes but is not biologically implausible for someone with a higher starting weight. The SURMOUNT-1 population averaged a starting BMI of 38. Weight loss tends to front-load in the first six months and then plateau, so dose escalation does not always produce linear additional losses. Real-world data, including analyses from Truveta Research published in 2023, suggest outcomes in actual patients are somewhat lower than trial results, averaging closer to 15-18% total body weight loss.

Where does the social media noise diverge from clinical reality?

The biggest divergence is the implied universality of dramatic results. GLP-1 TikTok heavily selects for people who respond well. You are not seeing the 20-30% of trial participants who discontinue due to side effects, the people who lost 8% and stopped, or the ones who regained weight after stopping. A 2023 analysis in Obesity (Rubino et al.) showed that one year after stopping semaglutide, participants regained roughly two-thirds of their lost weight. Tirzepatide likely follows a similar pattern, though long-term cessation data is still limited. The dose-by-dose breakdown format also implies that escalating doses produce proportional results. That is not what the data shows consistently. Some patients plateau at 5mg and see minimal additional loss at higher doses. Others tolerate higher doses poorly. Presenting personal dose milestones as a roadmap for others is not clinically supportable.

What should you actually know?

Tirzepatide is a dual GIP and GLP-1 receptor agonist, which mechanistically separates it from semaglutide and likely explains some of its superior efficacy signal. It is FDA-approved as Zepbound for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Compounded tirzepatide is not equivalent to Zepbound, and the FDA has previously flagged concerns about compounded GLP-1 products. Any dose decision should involve a licensed clinician, not a TikTok weight-loss timeline. Results like 116 pounds over two years are real and can happen, but they represent an outcome at the optimistic end of the distribution. If your expectations are anchored to the best-case social media stories, you may be setting yourself up for disappointment or, worse, pushing for higher doses without clinical justification.